Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like...
Saved in:
| Published in | Frontiers in immunology Vol. 14; p. 1188523 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
03.08.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient’s condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN. |
|---|---|
| AbstractList | Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient's condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN.Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient's condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN. Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient’s condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN. |
| Author | Chen, Peng-Yu Li, Zi-Yun Cai, Sui-Qing |
| AuthorAffiliation | Department of Dermatology, Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou , China |
| AuthorAffiliation_xml | – name: Department of Dermatology, Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou , China |
| Author_xml | – sequence: 1 givenname: Peng-Yu surname: Chen fullname: Chen, Peng-Yu – sequence: 2 givenname: Zi-Yun surname: Li fullname: Li, Zi-Yun – sequence: 3 givenname: Sui-Qing surname: Cai fullname: Cai, Sui-Qing |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37600791$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uktv1DAQjlARLaV_gAPKkUsWJ7YThwuqVjwqVUJCcLYm9rh1ceJgO4WV-PE43aVqOeCLrZnvMeOZ58XR5Ccsipc12VAq-jfGjuOyaUhDN3UtBG_ok-KkbltW0aZhRw_ex8VZjDckH9ZTSvmz4ph2LSFdX58Uv7cQsfyCsw_pbbkF7Sfr7AhDFdBBQl0m_8uqEmerMYzgyglV8G4Xbayc_Y5lQFDJ-imWcVEKYzSLc7sy5fhK_2nTdc7Ms8MRp5QFzjVkhyV7vCieGnARzw73afHtw_uv20_V5eePF9vzy0qxtk-V6bRAMxjkhoHQoCgKgFZxyoTWOODQG26gqTvOsTc4cFBgtOCsoW3fM3paXOx1tYcbOYfcX9hJD1beBXy4khCSVQ5la9qmNpmlCWOArehbopggetC0M5xkrXd7rXkZRtQq9xTAPRJ9nJnstbzyt7ImjPL86Vnh9UEh-B8LxiRHGxU6BxP6JcomF56RvF4Lf_XQ7N7l7_wyoNkD8kxiDGjuITWR657Iuz2R657Iw55kkviHpGyCdYa5YOv-R_0Dbj_I7g |
| CitedBy_id | crossref_primary_10_12968_hmed_2024_0477 crossref_primary_10_1007_s40257_024_00866_z crossref_primary_10_3390_curroncol31110509 crossref_primary_10_3389_fimmu_2024_1414136 crossref_primary_10_1007_s40278_023_46067_y crossref_primary_10_1111_ijd_17479 |
| Cites_doi | 10.1080/19420862.2023.2180794 10.2147/CCID.S401286 10.1038/s41571-020-0352-8 10.1046/j.1523-1747.2000.00061.x 10.1007/s40265-022-01761-9 10.1186/s13601-018-0199-6 10.1038/s41586-019-1162-y 10.1016/j.jaad.2020.03.132 10.1093/ajhp/zxz189 10.1200/JCO.2021.39.15_suppl.4101 10.1038/s41467-017-02358-7 10.1016/j.eclinm.2021.100951 10.1016/j.jhep.2022.03.039 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Chen, Li and Cai. Copyright © 2023 Chen, Li and Cai 2023 Chen, Li and Cai |
| Copyright_xml | – notice: Copyright © 2023 Chen, Li and Cai. – notice: Copyright © 2023 Chen, Li and Cai 2023 Chen, Li and Cai |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2023.1188523 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals - NZ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_6f621f699d044ae68960c480dbd37f50 PMC10435079 37600791 10_3389_fimmu_2023_1188523 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Case Reports |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c469t-f7d8efbfe5f4a8dac3e8aa6c5348ddebeb9f5fa21755e9feb5acafd8542369943 |
| IEDL.DBID | M48 |
| ISSN | 1664-3224 |
| IngestDate | Wed Aug 27 01:31:38 EDT 2025 Thu Aug 21 18:40:28 EDT 2025 Fri Jul 11 10:27:21 EDT 2025 Sat Aug 02 01:41:21 EDT 2025 Tue Jul 01 03:33:32 EDT 2025 Thu Apr 24 23:05:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Cadonilimab/AK104 case report immune checkpoint inhibitor Adalimumab immune-related adverse events toxic epidermal necrolysis |
| Language | English |
| License | Copyright © 2023 Chen, Li and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c469t-f7d8efbfe5f4a8dac3e8aa6c5348ddebeb9f5fa21755e9feb5acafd8542369943 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 These authors have contributed equally to this work and share first authorship Edited by: Mauro Alaibac, University of Padua, Italy Reviewed by: Tibor Bakacs, Alfred Renyi Institute of Mathematics, Hungary; Tomoya Watanabe, Yokohama City University, Japan; Raghwendra Mishra, Ananda Mohan College, India |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2023.1188523 |
| PMID | 37600791 |
| PQID | 2854350514 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6f621f699d044ae68960c480dbd37f50 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10435079 proquest_miscellaneous_2854350514 pubmed_primary_37600791 crossref_primary_10_3389_fimmu_2023_1188523 crossref_citationtrail_10_3389_fimmu_2023_1188523 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-03 |
| PublicationDateYYYYMMDD | 2023-08-03 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Geisler (B5) 2020; 83 Bertrand (B11) 2017; 8 Pang (B2) 2023; 15 Esfahani (B6) 2020; 17 Zhu (B13) 2021; 37 Keam (B1) 2022; 82 Zhang (B9) 2023; 16 Chuah (B12) 2022; 77 Wang (B10) 2018; 8 Bastuji-Garin (B3) 2000; 115 Bai (B4) 2021; 39 Perez-Ruiz (B8) 2019; 569 Choi (B7) 2019; 76 |
| References_xml | – volume: 15 start-page: 2180794 year: 2023 ident: B2 article-title: Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity publication-title: mAbs doi: 10.1080/19420862.2023.2180794 – volume: 16 year: 2023 ident: B9 article-title: Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S401286 – volume: 17 year: 2020 ident: B6 article-title: Moving towards personalized treatments of immune-related adverse events publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-020-0352-8 – volume: 115 year: 2000 ident: B3 article-title: SCORTEN: a severity-of-illness score for toxic epidermal necrolysis publication-title: J Invest Dermatol doi: 10.1046/j.1523-1747.2000.00061.x – volume: 82 year: 2022 ident: B1 article-title: Cadonilimab: First Approval publication-title: Drugs doi: 10.1007/s40265-022-01761-9 – volume: 8 start-page: 12 year: 2018 ident: B10 article-title: Diverse expression of TNF-α and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis publication-title: Clin Trans Allergy doi: 10.1186/s13601-018-0199-6 – volume: 569 year: 2019 ident: B8 article-title: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy publication-title: Nature doi: 10.1038/s41586-019-1162-y – volume: 83 year: 2020 ident: B5 article-title: Immune checkpoint inhibitor-related dermatologic adverse events publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2020.03.132 – volume: 76 year: 2019 ident: B7 article-title: Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma publication-title: Am J health-syst pharmacy: AJHP: Off J Am Soc Health-Syst Pharmacists doi: 10.1093/ajhp/zxz189 – volume: 39 year: 2021 ident: B4 article-title: Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.15_suppl.4101 – volume: 8 start-page: 2256 year: 2017 ident: B11 article-title: TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma publication-title: Nat Commun doi: 10.1038/s41467-017-02358-7 – volume: 37 start-page: 100951 year: 2021 ident: B13 article-title: Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.100951 – volume: 77 year: 2022 ident: B12 article-title: Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2022.03.039 |
| SSID | ssj0000493335 |
| Score | 2.3750813 |
| Snippet | Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1188523 |
| SubjectTerms | Adalimumab Adalimumab - therapeutic use Antibodies, Bispecific - adverse effects Antibodies, Bispecific - therapeutic use Cadonilimab/AK104 Carcinoma, Hepatocellular - drug therapy case report Humans immune checkpoint inhibitor Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use immune-related adverse events Immunology Liver Neoplasms - drug therapy Male Middle Aged Stevens-Johnson Syndrome - drug therapy Stevens-Johnson Syndrome - etiology toxic epidermal necrolysis Treatment Outcome Withholding Treatment |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SEHwp1s-1VSL4Jmv3Nslu0jc9WoqgTxb6FvJJV-_2Su8WLPSP70yyd9yJ1BdfN8kmZGYyv0nmg5APvMXntdqWAEdjyWPNQeZ8VbY8SOtba6vkPP7te3N-wb9eisutUl_oE5bTA-eNO25iU09io5SvODehkQC5HZeVt561MVvroPO2jKmfGfcyxkSOkgErTB3Hbj4fPmGxcDglpBQ129FEKWH_31Dmn86SW9rn7CnZH2Ej_ZyXe0Aehf4ZeZwLSd4-J3dTUEY0g-kTOjUeJHXWzY0tU6xK8HS1-N05GrAeLBzFM9oDXFykdCTlrPsVKGDHFOGwpMsh1VDEe_lbmvzQYThe10LL9drbHJbiAcHPB5jjBbk4O_0xPS_HugqlA2N4VcbWyxBtDCJyI71xLEhjGicYl3Da2WBVFNGAsSJEUDFYYZyJXgqAXkAIzl6SvX7Rh9eEtsoKB5oucMl5bRoblUOLSAorPBehIJP1Hms3Jh3H2hczDcYH0kUnumikix7pUpCPmzHXOeXGg72_IOk2PTFddvoATKRHJtL_YqKCvF8TXoN44ZuJ6cNiWGoMMGUCk8QX5FVmhM1U6E9UtWpSELnDIjtr2W3pu6uUwhuMYPhrq978j9Ufkie4I8ktkR2RvdXNEN4CVFrZd0kq7gELGRVI priority: 102 providerName: Directory of Open Access Journals |
| Title | Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37600791 https://www.proquest.com/docview/2854350514 https://pubmed.ncbi.nlm.nih.gov/PMC10435079 https://doaj.org/article/6f621f699d044ae68960c480dbd37f50 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKERIXRPkM0MpI3FBKdm0nDhJC7YpSIZUTK-3N8icNZJOyu5G6Ej-eGSe7YlHhwCWHJE4sT8bznjOeR8grXuDvtbFJAY6GlIcxB59zWVpwL40rjMli8vjF5_x8yj_NxGyPbOSOhgFc3kjtUE9quqiPr3-s34PDv0PGCfH2Tajm8-4YdcBhApASqNUtchsiU4GKBhcD3P_Wo2HGmOj3zvyl6U58imX8b8Kef6ZQ_haTzu6TewOYpCe99Q_Inm8ekDu9vOT6Ifk5gRBFe4j9lk60A_-tq7k2adzB4h1dtdeVpR5VYmGCrmkDILKNRUrSuvruKSDKuO9hSZddVFbE1fo1jdnp0BwXceHK1SYHHbriANfPO3jHIzI9-_Blcp4OagupBYq8SkPhpA8meBG4lk5b5qXWuRWMS5gDjTdlEEEDhRHCl8Eboa0OTgoAZHlZcvaY7Ddt458SWpRGWIh_nkvOxzo3obTIk6QwwnHhEzLajLGyQylyVMSoFVAStIuKdlFoFzXYJSGvt22u-kIc_7z7FE23vROLaMcT7eKrGnxS5SEfjwL03WWca59LYHOWy8wZx4ogsoS83BhegdPhnxTd-LZbKtx2ygSWjk_Ik_5D2L4Ks4yyohwlRO58Ijt92b3SVJexsDdQY3hqUT77_6bPyV0ch5iiyF6Q_dWi84cAm1bmKC43wPHjbHQU_eIXRDkfIA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Case+Report%3A+Cadonilimab-related+toxic+epidermal+necrolysis-like+reactions+successfully+treated+with+supplemental+Adalimumab&rft.jtitle=Frontiers+in+immunology&rft.au=Chen%2C+Peng-Yu&rft.au=Li%2C+Zi-Yun&rft.au=Cai%2C+Sui-Qing&rft.date=2023-08-03&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=14&rft_id=info:doi/10.3389%2Ffimmu.2023.1188523&rft.externalDocID=PMC10435079 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |